|
'Pathway Search Results'
- Selection criteria for significant gene list :
-
Significant genes are selected with a p value cut-off of 0.1. The resultant list was then sorted in a descending order of fold change value. From the sorted list, the top 100 genes were selected for pathway/network. If the gene list is less than 100, the entire gene list was taken for pathway/network analysis.
|
>>Total hits : 5
, Search term given : Bone AND Cancer
|
Estrogen receptor alpha/beta heterodimer action in response to estrogen and tamoxifen
|
GEO Description :
Expression profiling of U2OS osteosarcoma cell line expressing estrogen receptor/alpha heterodimer after treatment with 10 nM 17beta-estradiol (E2) or 10 nM 4-OH tamoxifen (4HT) for 24 hours. Results provide insight into the role of estrogen receptor/alpha heterodimer in gene regulation.
Organism : Homo sapiens
GEO-ID : GDS1094
|
|
|
- Compared Group :
- control Vs 17beta-estradiol
|
- Number of Nodes in the Network : 41
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 9.73000250234515e-19
- Fold Change Cut-Off : 2.02
|
|
|
- Compared Group :
- estrogen receptor beta Vs estrogen receptor alpha/beta
|
- Number of Nodes in the Network : 50
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 8.54575860352895e-15
- Fold Change Cut-Off : 2.15
|
|
|
- Compared Group :
- estrogen receptor alpha Vs estrogen receptor alpha/beta
|
- Number of Nodes in the Network : 55
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 7.90832364143537e-16
- Fold Change Cut-Off : 2.1
|
|
|
- Compared Group :
- estrogen receptor alpha Vs estrogen receptor beta
|
- Number of Nodes in the Network : 45
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 7.41658321670897e-15
- Fold Change Cut-Off : 2.03
|
|
|
- Compared Group :
- control Vs 4OH-tamoxifen
|
- Number of Nodes in the Network : 34
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 4.7280586563947e-12
- Fold Change Cut-Off : 2.0
|
DISCLAIMER:
The interactions, networks, list of genes/molecules or any other information presented here, is HYPOTHETICAL in nature and is based on information collected from public as well as other sources, and is analyzed by certain automated mining and analysis software workflows. Strandlife Science Pvt.Ltd. or the Editors of PathwayWorld offer this information with NO CLAIMS of accuracy and WARRANTIES of any kind, and DO NOT Accept liability or legal responsibility for losses allegedly caused by using this information.
GeneSpring® is a registered trademark of Agilent Technologies.
GeneSpring® is developed on AVADIS™ from Strand Life Sciences
|
